Welcome to our dedicated page for Xeris Biopharma Holdings SEC filings (Ticker: XERS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Xeris Biopharma Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Xeris Biopharma Holdings's regulatory disclosures and financial reporting.
Xeris Biopharma Holdings, Inc. officer Kevin McCulloch reported selling 15,000 shares of common stock at $8.00 per share on January 8, 2026. The sale was executed under a Rule 10b5-1 trading plan adopted by the reporting person. After this transaction, he beneficially owned 1,685,426 shares of common stock directly and 25,000 shares indirectly through his spouse. He serves as President and Chief Operating Officer of the company.
An insider has filed a Form 144 indicating an intention to sell 60,000 shares of common stock of issuer XERS through Morgan Stanley Smith Barney LLC on or around 01/08/2026, with the shares listed on the NASDAQ. The filing cites an aggregate market value of $432,600.00 for this planned sale.
The shares to be sold were acquired as restricted stock units from the issuer on 01/31/2021. As context, the filing notes that there were 165,924,289 shares of this class outstanding.
Xeris Biopharma Holdings, Inc. filed a current report to disclose that it has issued a press release with certain preliminary financial results for the fourth quarter and full year ended December 31, 2025. The press release is provided as Exhibit 99.1 and offers an early view of the company’s recent performance before final audited figures are available. The company states that this financial information, including Exhibit 99.1, is being furnished rather than filed, which affects how it is treated under securities laws.
Xeris Biopharma Holdings director reports preset stock sale. An Xeris Biopharma Holdings, Inc. director reported selling 15,000 shares of common stock on 12/12/2025, identified with transaction code "S." The shares were sold at a weighted average price of $7.0943 per share.
The disclosure states the transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After this sale, the director beneficially owns 142,500 shares of Xeris Biopharma common stock directly.
Xeris Biopharma Holdings (XERS) filed a Form 4 showing option exercises and a share sale by its Chief Executive Officer and Director. On 11/13/2025, the reporting person exercised stock options to acquire 8,970 shares of common stock at an exercise price of $1.55 per share and sold 23,242 shares of common stock at a weighted average price of $7.4607, all under a pre-arranged Rule 10b5-1 trading plan. After these transactions on that date, the reporting person held 2,643,153 shares of common stock directly. On 11/14/2025, the reporting person exercised additional stock options for 87,100 shares at $1.55 per share, increasing the directly held common stock position to 2,730,253 shares. Following these transactions, the person also held 64,265 stock options with an exercise price of $1.55 per share expiring on 02/03/2027.
Xeris Biopharma (XERS) reported an insider transaction by an officer. On 11/11/2025, the reporting person sold 16,667 shares of common stock at a weighted average price of $7.3976, executed under a Rule 10b5-1 trading plan.
Following the sale, the filer directly beneficially owned 1,336,843 shares. The sale price reflects multiple trades between $7.290 and $7.750. The reporting person is the company’s Chief Legal Officer and Corporate Secretary.
Xeris Biopharma reported stronger Q3 results. Total revenue reached $74.380 million (up 37.1% year over year), led by Recorlev $36.975 million, Gvoke $25.151 million, and Keveyis $11.937 million. Operating income was $6.731 million versus a loss a year ago, and net income was $621 thousand.
For the first nine months, revenue was $206.038 million with a net loss of $10.527 million. Cost discipline and mix improved gross costs: cost of goods sold fell to 14.8% of product revenue in Q3 from 25.7% a year earlier, aided by fewer inventory write-offs.
Cash and cash equivalents were $91.598 million and total cash, cash equivalents and restricted cash were $95.619 million. Net debt stood at $219.469 million (including $33.6 million of 2028 convertible notes and $188.045 million of 2029 loans). Stockholders’ equity (deficit) improved to $(0.861) million from $(29.615) million at year-end. Management believes cash resources are sufficient for at least the next 12 months, while noting ongoing net losses and market risks.
Xeris Biopharma Holdings, Inc. furnished an 8-K announcing a press release with results of operations and business highlights for the three and nine months ended September 30, 2025. The press release is included as Exhibit 99.1.
The company states the information in Item 2.02, including Exhibit 99.1, is being furnished and is not deemed “filed” under Section 18 of the Exchange Act, nor incorporated by reference except as specifically set forth.
Xeris Biopharma Holdings insider Kevin McCulloch, listed as President and Chief Operating Officer, reported a transaction dated 10/02/2025. The filing shows 733 shares of common stock were disposed of at $8.31; the explanation states these shares were withheld by the issuer to satisfy tax and withholding obligations in connection with the net settlement of restricted stock units that vested on that date. After the reported transaction, Mr. McCulloch beneficially owns 1,700,426 shares directly. The report also lists 25,000 shares held indirectly by his spouse, with the reporting person disclaiming beneficial ownership except for pecuniary interest.
Xeris Biopharma Holdings, Inc. (XERS) Form 4 discloses insider reporting by Kevin McCulloch, President and Chief Operating Officer. On September 11, 2025 Mr. McCulloch, acting as trustee of the Charles R. McCulloch Trust, caused the trust to distribute 2,000 shares of Xeris common stock to a trust beneficiary; the Form notes no sale occurred in the transfer. The filing reports Mr. McCulloch's beneficial ownership following the transaction as 1,701,159 shares and an indirect holding of 25,000 shares attributable to his spouse. The reporting person disclaims beneficial ownership of distributed shares except to the extent of pecuniary interest.